Merck’s drug less effective against moderate COVID – Indian regulatory source

by



[ad_1]

The Merck logo is seen at a door of the Merck & Co campus in Rahway, New Jersey, United States, on July 12, 2018. REUTERS / Brendan McDermid

NEW DELHI, October 8 (Reuters) – Merck & Co’s investigational antiviral drug molnupiravir (MRK.N) has not shown “significant efficacy” against moderate COVID-19, a source from the Drug Controller General of India.

Aurobindo Pharma Ltd wants to stop a late stage trial of molnupiravir in patients with moderate COVID-19, the regulator’s expert committee said on Friday. Read more

“There is no significant efficacy against moderate COVID and the actual efficacy is for mild cases,” the source said on condition of anonymity due to the sensitive nature of the discussions.

The regulator and the health ministry did not immediately respond to a request for comment.

Reporting by Neha Arora; edited by Jason Neely

Our Standards: Thomson Reuters Trust Principles.

[ad_2]

Source link